Receptor News and Research

RSS

SARS-CoV-2 vaccine based on vesicular stomatitis virus exhibits high neutralizing efficacy against variants

Scientists have tested the efficacy of BriLife®-vaccinated human sera in neutralizing more infectious and probably more virulent SARS-CoV-2 variants.

26 Nov 2021

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

In a literature review article published in the Journal of Community Hospital Internal Medicine Perspectives, authors from the US performed a thorough investigation of previous studies and case reports of SARS-CoV-2 reinfection. This review discusses the role of natural immunity, vaccines, and SARS-CoV-2 variants in reinfection.

25 Nov 2021

Study explores adverse effects of SARS-CoV-2-induced antibody responses

The authors of a research paper published in the journal Frontiers in Immunology used Sandwich ELISA tests to determine the distribution of IgG sub-classes and complement activation levels in plasma from convalescent individuals.

25 Nov 2021

Researchers reveal possible role for anti-idiotype antibodies in long-term effects of COVID-19

With around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field.

25 Nov 2021

Using metal nanoparticles to fight SARS-CoV-2

A recent review article looks at the potential of nanotechnology in fighting severe acute respiratory syndrome 2 (SARS-CoV-2), with several possibilities of strategies in therapeutics, vaccines, and prevention.

25 Nov 2021

COVID-19 vaccine boosters to prevent breakthrough SARS-CoV-2 infections in healthy adults

Researchers measured anti-RBD IgG and virus neutralization before and after vaccination with boosters.

25 Nov 2021

Researchers investigate Moderna COVID-19 vaccine efficacy

Researchers have been investigating the vaccine efficacy of the mRNA-1273 vaccine.

25 Nov 2021

SARS-CoV-2 Delta variant mutation sites

A new review article dissected the sites of mutation in the RBD of the Delta variant and other variants of concern and variants of alert and interest.

25 Nov 2021

New, improved organoids shed light on untreatable form of prostate cancer

A multi-institutional team of investigators led by bioengineer Ankur Singh has developed research tools that shed new light on a virtually untreatable form of prostate cancer, opening a pathway that may lead to novel therapeutics and a glimmer of hope for patients.

24 Nov 2021

Can COVID-19 affect erectile function?

Researchers discuss the underlying mechanisms through which COVID-19 can affect erectile function.

24 Nov 2021

Acute SARS-CoV-2 infection during pregnancy associated with placental ACE2 shedding

A new study, published on the bioRxiv* preprint server, hypothesized that ACE-2 expression and ADAM17 activity in the placenta is affected by the timing of SARS-CoV-2 infection of the mother.

24 Nov 2021

Treatment with antihistamines associated with improved responses to immunotherapy

New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.

24 Nov 2021

SARS-CoV-2 reinfection and the natural immune response

Researchers review available literature on immunity and SARS-CoV-2 infection to elucidate mechanisms behind SARS-CoV-2 immunity and reinfections.

24 Nov 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021